2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

ACT Genomics

Company Presentations

Friday, July 24 Company Presentations 5–Diagnostics, Device, NPO

ACT Genomics

Company Info

Name /ACT Genomics

Address /3F., No.345, Xinhu 2nd Rd., Neihu Dist., Taipei City 114, Taiwan (R.O.C.)

Website /www.actgenomics.com/en

Presenter

Name /Shu Jen Chen

Title /Chief Scientific Officer

Email /

Telephone /(Work) +886 2 2795 3660 # 1500

Fax /+886 2 2795 5016

Mobile /

Company Type

Biotechnology,Diagnostics

About the Company

To get the whole picture of molecular profile in cancer, ACT Genomics’ technology overcomes genomic sequencing barrier for a broad application. Served as the genomic lens, ACT Genomics leads innovative integration among clinical treatment, cancer research and drug development, ensuring personal medical journey with better quality of life. ACT Genomics’ services covers cancer patients’ treatment and their families’ prevention; difficult situations in late-stage cancer can be managed with ACT Genomics’ superior panel design.

Based in Asia, ACT Genomics’ premium-quality database featuring high success rate in sequencing and top-notch bioinformatics analysis offers new direction for Precision Medicine.

Brief Description of main products or services

  1. Cancer Treatment for Solid Tumor Patients & for Research Use

    ACT Genomics provides NGS-based multiple genomic profiling options for tumor cell according to clinical needs. Report turnaround time ranges from 12-14 calendar days.

    Tissue Sample
    ACTOnco®+sequences 440 genes for comprehensive treatment selection from immunotherapy, targeted therapy, hormonal therapy and chemotherapy.
    ACTDrug®+sequences 40 genes for general targeted therapy selection
    ACTFusion™sequences 31 genes for certain targeted therapy selection
    ACTBRCA®& ACTBRCA®HRDsequence 2- 48 genes for PARP Inhibitor evaluation only
    Liquid Sample
    ACTMonitor®+sequence 8-50 genes for monitoring recurrence caused by drug resistance
    ACTCerebra™sequences 40 genes for targeted therapy selection for patients with brain metastases
  2. Cancer Prevention for Patients’ Family

    ACT Genomics provides NGS-based genomic profiling option for hereditary risk evaluation according to clinical needs. Report turnaround time is 30 calendar days.

    Liquid Sample
    ACTRisk™sequences 32 genes for 8 inherited cancer risk evaluation
  3. Cancer Drug Development for Research Use

    ACT Genomics provides chip-based multiplex PCR genomic profiling option for tumor microenvironment according to research needs. Report turnaround time in 2 hours.

    Tissue Sample
    ACTTME™sequences 32 genes for tumor microenvironment research

Contact Person

Name /Luke Chen

Email /lukechen@actgenomics.com

Phone /0919-217-179